“We rate PRGO Overweight and have a 12-month price target of $107. Perrigo has been through a lot over the past two years, but we think the Street can finally refocus on fundamentals. This should drive a greater appreciation for the company’s growth prospects and earnings potential, in our view. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $107.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 8.9% and a 41.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Perrigo Company plc has an analyst consensus of Hold, with a price target consensus of $81.63.
Perrigo Company plc’s market cap is currently $9.89B and has a P/E ratio of 43.86. The company has a Price to Book ratio of 1.70.
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRGO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Perrigo Co. Plc is a healthcare company, which engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals.